NASDAQ$FDMT
4D Molecular Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Announced financial results and provided operational highlights.
4D Molecular Therapeutics reported Q3 2021 financial results, including total revenue of $1.4 million and a net loss of $22.2 million. The company highlighted clinical data updates on three programs and the clearance of IND applications for two product candidates. A public offering of common stock resulted in net proceeds of approximately $111 million, strengthening the balance sheet.
- Provided clinical data updates on 3 programs, including first-ever clinical activity data from two 4DMT targeted and evolved vectors: C102 for systemic low dose cardiovascular delivery and R100 for routine intravitreal delivery.
- Announced the pricing of a public offering of common stock with expected total gross proceeds of approximately $119 million.
- Received clearance from the U.S. Food and Drug Administration (FDA) for the 4DMT Investigational New Drug (IND) Applications for the Phase 1/2 clinical trials of 4D-150 for wet age-related macular degeneration (wet AMD) and of 4D-710 for cystic fibrosis.
- Received clearance from the Taiwan Food and Drug Administration for the 4DMT Investigational New Drug (IND) Application for the Pacific Rim Phase 1/2 clinical trial of 4D-310 for Fabry disease.
Headline financials
Revenue & EPS history
4DMT · Revenue · Quarterly
$1.37M
Revenue by segment
4DMT · $1.37M total across 1 segment · Q3 2021
- Collaboration & license rev.$1.37M—100.0%
Forward guidance
4DMT expects to have five product candidates in clinical development in three different therapeutic areas in 2022 and expects cash and cash equivalents, inclusive of net proceeds from the offering, to be sufficient to fund operations into the second half of 2024.
Tailwinds
- Interim clinical data from the Phase 1/2 clinical trial of 4D-310 in Fabry disease expected in 2022
- First patient dosing in the 4D-150 Phase 1/2 clinical trial for wet AMD expected in the first quarter of 2022
- First patient dosing in the 4D-710 Phase 1/2 clinical trial for cystic fibrosis expected in the first half of 2022
- Continued enrollment in both the 4D-125 for x-linked retinitis pigmentosa and 4D-110 for choroideremia Phase 1/2 clinical trials
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+20.0%
Q3 2022
Best reaction
-10.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.6% | -0.7% | -17.3% | |
| Q4 2025 | +7.3% | +7.2% | +22.5% | |
| Q3 2025 | +6.7% | +6.1% | +7.4% | |
| Q1 2025 | +9.9% | +4.7% | +27.0% | |
| Q4 2024 | -8.6% | -8.6% | -28.7% | |
| Q3 2024 | +1.9% | +5.7% | -17.4% | |
| Q2 2024 | +0.6% | +1.6% | +2.4% | |
| Q1 2024 | -2.4% | -2.2% | -13.7% | |
| Q4 2023 | +5.3% | -3.0% | +14.2% | |
| Q3 2023 | +1.8% | +2.2% | +37.7% | |
| Q2 2023 | -1.6% | -1.1% | -7.4% | |
| Q1 2023 | -2.5% | +2.8% | +26.8% | |
| Q4 2022 | -0.7% | -5.4% | -12.5% | |
| Q3 2022 | +20.0% | +66.3% | +188.5% | |
| Q2 2022 | -10.4% | -12.5% | -14.9% | |
| Q1 2022 | -3.1% | -12.9% | -31.5% | |
| Q4 2021 | +8.1% | +1.6% | -22.5% | |
| Q3 2021 | -0.7% | -3.8% | -12.1% | |
| Q2 2021 | -4.0% | +5.2% | +19.4% | |
| Q1 2021 | -3.9% | -3.4% | +2.6% | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro